Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes mellitus
Sign Up to like & getrecommendations! Published in 2020 at "Medicina Clinica"
DOI: 10.1016/j.medcle.2019.05.014
Abstract: Abstract Introduction Oral antidiabetic inhibitors of the sodium-glucose cotransporter (SGLT2i) reduce cardiovascular morbidity and mortality in DM2. The increase in arterial stiffness can participate in this morbidity and mortality. The aim of this study was… read more here.
Keywords: dapagliflozin arterial; stiffness; stiffness patients; arterial stiffness ... See more keywords
Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study
Sign Up to like & getrecommendations! Published in 2023 at "Diabetes"
DOI: 10.1111/dom.15033
Abstract: To evaluate the albuminuria‐lowering effect of dapagliflozin, exenatide, and the combination of dapagliflozin and exenatide in patients with type 2 diabetes and microalbuminuria or macroalbuminuria. read more here.
Keywords: exenatide combination; patients type; effect dapagliflozin; lowering effect ... See more keywords
Cardio-protective effect of dapagliflozin against doxorubicin induced cardiomyopathy in rats.
Sign Up to like & getrecommendations! Published in 2022 at "European review for medical and pharmacological sciences"
DOI: 10.26355/eurrev_202206_29079
Abstract: OBJECTIVE Cancer is the second most common non-communicable disease group in the world and its frequency is increasing. In parallel, side effects of drugs used in cancer treatment are frequently encountered. Doxorubicin (DOX) is one… read more here.
Keywords: effect dapagliflozin; dox; doxorubicin; group ... See more keywords